Gilead Sciences is snapping up a subsidiary of Nimbus Therapeutics for access to its experimental therapy for a metabolic disorder causing fat buildup in the liver.
The firm is prepared to shell out $1.2 billion under the deal; $400 million for Nimbus Apollo and a further $800 million to parent company Nimbus Therapeutics if certain developmental, regulatory and sales milestones are met.
The Nimbus Apollo programme includes lead candidate NDI-010976, an ACC inhibitor, and other preclinical ACC inhibitors for the treatment of non-alcoholic steatohepatitis (NASH), and for the potential treatment of hepatocellular carcinoma (HCC) and other diseases.
NDI-010976 was granted Fast Track designation by the US Food and Drug Administration in February; Phase I data for the compound are to be presented next month during at The International Liver Congress 2016, the annual meeting of the European Association for the Study of the Liver (EASL).
NASH is a serious liver disease resulting from metabolic dysfunction that causes toxic build-up of fat in the liver (steatosis) that can lead to inflammation, hepatocellular injury, progressive fibrosis and cirrhosis. The condition currently affects up to 15 million people in the US and, as Gilead notes, is expected to become the leading indication for liver transplantation by 2020.
“The acquisition of Nimbus’ ACC-inhibitor program represents a timely and important opportunity to accelerate Gilead’s ongoing efforts to address unmet needs in NASH,” said Norbert Bischofberger, Gilead’s chief scientific officer. “These molecules will complement and further strengthen Gilead’s pipeline and capabilities to advance a broad clinical program in NASH that includes compounds targeting multiple key pathways involved in the pathogenesis of the disease.”
By Selina McKee
Source: Pharma Times
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
